PT - JOURNAL ARTICLE AU - Birkenbihl, Colin AU - de Jong, Johann AU - Yalchyk, Ilya AU - Fröhlich, Holger AU - , TI - Deep learning-based patient stratification for prognostic enrichment of clinical dementia trials AID - 10.1101/2023.11.25.23299015 DP - 2023 Jan 01 TA - medRxiv PG - 2023.11.25.23299015 4099 - http://medrxiv.org/content/early/2023/11/27/2023.11.25.23299015.short 4100 - http://medrxiv.org/content/early/2023/11/27/2023.11.25.23299015.full AB - Dementia probably due to Alzheimer’s disease (AD) is a progressive condition that manifests in cognitive decline and impairs patients’ daily life. Affected patients show great heterogeneity in their symptomatic progression, which hampers the identification of efficacious treatments in clinical trials. Using artificial intelligence approaches to enable clinical enrichment trials serves a promising avenue to identify treatments.In this work, we used a deep learning method to cluster the multivariate disease trajectories of 283 early dementia patients along cognitive and functional scores. Two distinct subgroups were identified that separated patients into ‘slow’ and ‘fast’ progressing individuals. These subgroups were externally validated and independently replicated in a dementia cohort comprising 2779 patients. We trained a machine learning model to predict the progression subgroup of a patient from cross-sectional data at their time of dementia diagnosis. The classifier achieved a prediction performance of 0.70 ± 0.01 AUC in external validation.By emulating a hypothetical clinical trial conducting patient enrichment using the proposed classifier, we estimate its potential to decrease the required sample size. Furthermore, we balance the achieved enrichment of the trial cohort against the accompanied demand for increased patient screening. Our results show that enrichment trials targeting cognitive outcomes offer improved chances of trial success and are more than 13% cheaper compared to conventional clinical trials. The resources saved could be redirected to accelerate drug development and expand the search for remedies for cognitive impairment.Competing Interest StatementJDJ is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. The company had no influence on the scientific results of this study.Funding StatementThis project was partially funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 826421, 'TheVirtualBrain-Cloud'.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only existing public datasets were used.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe used datasets are publicly available at https://adni.loni.usc.edu/ and https://naccdata.org/.